PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

(2019) Ryan J. Sullivan et al.   NATURE MEDICINE

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

(2019) Paolo Antonio Ascierto et al.   NATURE MEDICINE

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

(2019) Antoni Ribas et al.   NATURE MEDICINE

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

(2018) Paul G. Baverel et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

(2018) Anais Del Curatolo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

(2017) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

(2016) Daniele Ouellet et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

HISAT: a fast spliced aligner with low memory requirements

(2015) Daehwan Kim et al.   NATURE METHODS

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

(2014) G. S. Falchook et al.   CLINICAL CANCER RESEARCH

Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges

(2014) Siwen Hu-Lieskovan et al.   JOURNAL OF CLINICAL ONCOLOGY

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

(2014) Daniele Ouellet et al.   JOURNAL OF CLINICAL PHARMACOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Marked, Homogeneous, and Early [18F]Fluorodeoxyglucose–Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma

(2012) Grant A. McArthur et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE